About Esprit Pharma
Esprit Pharma is a company based in East Brunswick (United States) founded in 2005 was acquired by Allergan in September 2007. Esprit Pharma has raised $219.49 million across 4 funding rounds from investors including Fortress Investment, Apax Partners and Allergan. Esprit Pharma operates in a competitive market with competitors including Lipella, TheraVida, Regenfro Co, Kissei Pharmaceutical and Acerus Pharma, among others.
- Headquarter East Brunswick, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Esprit Pharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$219.49 M (USD)
in 4 rounds
-
Latest Funding Round
$25 M (USD), Series B
Jan 16, 2007
-
Investors
Fortress Investment
& 6 more
-
Employee Count
Not available
-
Acquired by
Allergan
(Sep 19, 2007)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Esprit Pharma
Esprit Pharma has successfully raised a total of $219.49M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in January 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Esprit Pharma
Esprit Pharma has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Fortress Investment, Apax Partners and Allergan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Equity investments are focused on tech, services, and consumer sectors.
|
Locked | Locked | Locked | |
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Esprit Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Esprit Pharma
Investment portfolio details for Esprit Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Esprit Pharma
Detailed financials for Esprit Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Esprit Pharma Comparisons
Peer comparison for Esprit Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Esprit Pharma
Esprit Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lipella, TheraVida, Regenfro Co, Kissei Pharmaceutical and Acerus Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Lipid-based therapies for common bladder syndromes are developed.
|
|
| Locked | Locked | Locked |
Clinical stage biopharma company developing drugs for urology and central nervous system disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat renal diseases
|
|
| Locked | Locked | Locked |
Therapies for renal diseases and urology-related anemia are developed.
|
|
| Locked | Locked | Locked |
Develops pharmaceuticals for urology, hormone replacement therapy, and female sexual dysfunction treatments.
|
Detailed competitors of Esprit Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Esprit Pharma
Complete news archive for Esprit Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Esprit Pharma
Esprit Pharma was founded in 2005.
Esprit Pharma is headquartered in East Brunswick, United States. It is registered at East Brunswick, New Jersey, United States.
Esprit Pharma is a funded company, having raised a total of $219.49M across 4 funding rounds to date.
Esprit was focussed on developing drugs for genitourinary and womens health. It had marketed products Sanctura (trospium chloride) for the treatment of overactive bladder (OAB) and Sanctura XR is indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency and urinary frequency. In September 2007, Allergan acquired Espirit for 370M.
Esprit Pharma's top competitors include Lipella, Kissei Pharmaceutical and Regenfro Co.
Esprit Pharma has 7 investors. Key investors include Fortress Investment, Apax Partners, Allergan, Greenspring Associates, and NEA.